---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-004067"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-12-16T23:59:59+00:00"
generated_at: "2026-05-16T13:06:41.448554+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silexion submits Phase 2/3 trial application for SIL204 in locally advanced pancreatic cancer

## Summary
- Submitted Phase 2/3 clinical trial application in Israel for SIL204, a siRNA therapy for locally advanced pancreatic cancer (LAPC).
- Phase 2/3 trial initiation planned for Q2 2026; follow-on regulatory filings in Germany/EU in Q1 2026.
- Preclinical data demonstrated up to 99.7% cancer cell inhibition across multiple KRAS mutations.
- Two completed species toxicology studies confirmed no systemic organ toxicity; positive German regulatory feedback received.
- Collaborating with Sheba Medical Center (top-10 global hospital) for Israeli trial; U.S. expansion after safety run-in.

## SEC filing metadata
- accession: 0001178913-25-004067
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325004067/0001178913-25-004067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325004067/zk2534113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-004067
- JSON: https://secwatch.observer/filing/0001178913-25-004067.json
- Plain text: https://secwatch.observer/filing/0001178913-25-004067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.